NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout

    India
    Business
    World
    Politics
    Sports
    Technology
    Entertainment
    Auto
    Lifestyle
    Inspirational
    Career
    Bengaluru
    Delhi
    Mumbai

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
    Home / News / World News / FDA rejects emergency-use approval of Bharat Biotech's COVAXIN
    Next Article
    FDA rejects emergency-use approval of Bharat Biotech's COVAXIN
    The US FDA has rejected Bharat Biotech's application for an emergency use authorization for COVAXIN.

    FDA rejects emergency-use approval of Bharat Biotech's COVAXIN

    By Sagar
    Jun 11, 2021
    02:22 pm

    What's the story

    The United States' top drug regulator - the Food and Drug Administration - has rejected Bharat Biotech's application for an emergency use authorization for its COVID-19 vaccine COVAXIN.

    The authorities have asked for additional information and data for the vaccine, effectively delaying its potential launch in the US.

    Bharat Biotech's partner in the US says it would now seek a full approval.

    Details

    Company says it would now apply for a full approval

    The FDA has rejected the approval request as Bharat Biotech had submitted partial trial data from March this year, and data from an additional clinical trial would be required, according to Hindustan Times.

    Ocugen, Bharat Biotech's partner in the US, said it would skip the emergency use authorization and instead apply for a Biological License Application (BLA) or full approval at a later time.

    Quote

    'Committed to bringing COVAXIN to the US'

    "The FDA provided feedback to Ocugen regarding the Master File submitted previously and recommended that we pursue a BLA submission instead of an EUA application for the vaccine candidate and requested additional information and data," Ocugen said in a statement to the New York Stock Exchange.

    "While this will extend our timelines, we're committed to bringing COVAXIN to the US," the company's CEO said.

    Vaccine

    COVAXIN is 78% effective against symptomatic disease

    COVAXIN is India's only approved indigenous coronavirus vaccine.

    It is currently one of the three vaccines being used in India's nationwide inoculation program, that began in January.

    As per an interim analysis, the vaccine was found to be 78% effective against symptomatic COVID-19 disease and 100% effective in providing protection from serious illness.

    Phase-3 data

    COVAXIN has not furnished phase-3 trial data yet

    The rejection from the US health officials comes at a time when Bharat Biotech is facing criticism in India for failing to share its phase-3 trial data even six months after the vaccine was granted emergency use approval in India.

    In January, the company had said it would submit results by March, but recently stated the data would be made public only in July.

    Recognition

    Many countries do not yet recognize COVAXIN

    COVAXIN has been facing troubles securing approvals in foreign countries and from the World Health Organization (WHO).

    International recognition is essential for the company to start widely exporting its vaccine and become part of the "vaccine passport" - under which fully vaccinated people would be allowed to travel abroad.

    Countries that have approved the jab include Iran, Philippines, Mauritius, Mexico, Nepal, Guyana, and Zimbabwe.

    Information

    US universities ask students who took COVAXIN to get re-vaccinated

    In fact, universities across the US are asking foreign students to get re-vaccinated if they have been inoculated with vaccines that don't yet have the approval from the WHO. This includes Indian students who may have taken COVAXIN or the Russian vaccine Sputnik V's shots.

    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Latest
    Coronavirus
    COVAXIN

    Latest

    Crystal Palace win the FA Cup 2024/25 title: Key stats FA Cup
    KKR knocked out of IPL 2025 after washout versus RCB Kolkata Knight Riders (KKR)
    Jasmine Paolini makes history by winning 2025 Italian Open: Stats Coco Gauff
    White pigeons pay tribute to Virat Kohli during RCB-KKR clash Virat Kohli

    Coronavirus

    EPFO members allowed second advance withdrawal citing COVID-19 Employees' Provident Fund Organisation (EPFO)
    COVID-19 variants found in India named 'Kappa' and 'Delta' World Health Organization
    Coronavirus: India recorded world's highest infections, deaths in May Ministry of Health and Family Welfare
    Goa's COVID-19 positivity rate drops to 20% in one month Goa

    COVAXIN

    South Africa: COVID-19 vaccine to arrive on February 1 India
    UN Chief lauds India's COVID-19 vaccine assistance to nations India
    Expert panel recommended against granting EUA to Pfizer's vaccine: Officials Pfizer
    Twenty-five countries in queue for Made in India COVID-19 vaccine S Jaishankar
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2025